짧고 검은 머리에 안경을 쓴 남색 블레이저와 하늘색 셔츠를 입은 남성이 기업 법률 사무실에서 미소를 짓고 있습니다.

벤자민 A. 버코위츠

파트너

벤자민 A. 버코위츠

파트너

Dr. Benjamin (Benny) Berkowitz counsels innovative clients as they develop new products, protects their groundbreaking inventions, and helps them maximize the value of their intellectual property in furtherance of business goals and strategy.

A partner and IP chair of the Washington, D.C., office of Foley & Lardner LLP, Benny counsels clients on legal and strategic issues related to IP, drafts and prosecutes patent applications in the United States and abroad, and evaluates IP for due diligence analyses and freedom-to-operate opinions. Benny has prosecuted a variety of chemical, biochemical, and mechanical patents in a broad spectrum of technologies, including plant molecular biology, antibodies, chemical sensors, optical equipment, small molecules, polymers, and pharmaceuticals. He practices in the firm’s Chemical, Biotechnology & Pharmaceutical, and International Practice Groups, and the Innovative Technology Sector, for which he serves as chair of the Health Tech & Genomics area of focus. He previously chaired the firm’s National Associates Committee.

Benny also counsels companies on due diligence matters for business deals and securities offerings. He has served as lead IP counsel for companies in deals totaling more than US$4.2 billion and worked with numerous companies in securities offerings, including IPOs.

Benny maintains a niche practice in helping companies receive IP protection on plant varieties, including plant breeder’s rights protection, plant patents, and PVPA protection.

ベンジャミン・バルコウィッツは、フォーリー&ラードナーLLPワシントンDCオフィス知的財産権法部門のパートナーである。法律上及び戦略上の課題に関して、知的財産権、米国内と海外の特許出願の起草や訴訟、IPディリジェンス分析と営業する自由の意見を評価することについて顧客に法的助言する経験を有する。植物分子生物学、抗体、科学センサー、光学機器、小分子、ポリマー、医薬品などの幅広い技術分野で様々な化学、生化学および機械的な特許を訴訟した。同社の科学、バイオテクノロジー、化学製品プラクティスグループならびにライフサイエンス産業チームに所属する。さらに、同社のナショナルアソシエイト委員会の議長を務めた。

また、商取引や証券取引のIPディリジェンスの課題について企業に助言する。総額12億ドルを超える取引で、企業のIP知的財産法律顧問を務め、IPOを含む証券取引所の多くの企業と協力していた。

植物育種者の権利保護、植物の特許、PVPAの保護などの植物の品種に対する知的財産保護を企業に提供し、稀な業務を担当している。

受賞

2009年に、知的財産権、特許訴訟や植物特許に対してLegal 500に選出された。

学歴 ・経歴

コロンビア大学卒業(科学工学学士号、1994年)。 イェール大学卒業(分子生物学及び生化学博士号、2001年)。ジョージタウン大学ロースクルー卒業(法学博士号、優等(cum laude)で取得、2006年)。 ロースクールに通う中、連邦巡回控訴裁判所でArthur Gajarsa 判事の下でインターンシップをした。

자격

バージニア州、ニューヨーク州とコロンビア特別区の弁護士資格を有する。連邦最高裁判所、連邦控訴裁判所連邦巡回区裁判所および米国特許商標庁で弁論を行う資格を有する。

著書・論文等

  • Benjamin Berkowitz and Stephen Maebius, “United States: Reforms Include Post-Grant Opposition,” Managing Intellectual Property, October 2008
  • George Best, Benjamin Berkowitz, and Stephen Maebius, “How Damaged Is the Patent Reform Act?” Legal Times, July 7, 2008
  • Berkowitz B, Huang DB, Chen-Park FE, Sigler PB, Ghosh G, “The x-ray crystal structure of the NF-kappa B p50.p65 heterodimer bound to the interferon beta -kappa B site,” J Biol Chem. 2002 Jul 5;277(27):24694-700
  • “Intellectual Property Protection for Plant Inventions – A Practical Guide for the U.S.,” Tel Aviv Israel, May 26, 2008
  • “Patent Reform 2008: The Current Debate and Its Implications for Biotech,” Tel Aviv, Israel, May 26, 2008
  • “Patent Reform Act of 2008: The Current Debate and Its Implications for Biotech,” New York Biotechnology Association Meeting, May 18, 2008
  • “New USPTO Continuations and Claim Rules and Their Practical Implications,” Tel Aviv, Israel, November 5, 2007
  • “Practical Considerations in Restriction Practice,” Tel Aviv, Israel, Summer 2007

수상 및 표창

  • Legal 500 – Intellectual Property, Patent Prosecution and Plant Patents (2009).

프레젠테이션 및 출판물

  • “Cancer Drugs: Antibody Drug Conjugates (ADCs) Keep Growing,” Health Care Law Today (March 12, 2024)
  • “U.S. Pharmaceutical Patent Litigation Developments,” Japan Pharmaceutical Manufacturers Association, U.S. Patent Law Seminar Series – 2020-2022 (Nov. 16, 2022)
  • “U.S. Patent Counseling Update: USPTO Statistics, New Programs, and Federal Circuit Cases,” Japan Intellectual Property Association, U.S. Intellectual Property Law Update Seminar Series – First Half of 2022 (Sept. 8, 2022)
  • Berkowitz B, Huang DB, Chen-Park FE, Sigler PB, Ghosh G, “The x-ray crystal structure of theNF-kappa B p50.p65 heterodimer bound to the interferon beta -kappa B site,” J Biol Chem. 2002 Jul 5;277(27):24694-700
2025년 9월 18일 행사

GLP-1 약물 집중 분석: 동향, 요구사항 및 향후 전망

폴리의 헬스케어·생명과학 및 혁신기술 부문에서 주최하는 웨비나에 여러분을 초대합니다. 본 웨비나에서는 귀사가 GLP-1 분야의 교차로에서 방향을 설정하고 진화하는 환경에 대비하는 방법을 논의할 예정입니다.
한 손으로 인슐린 펜을 들고 다른 손으로 뚜껑을 제거하는 모습은 시카고 변호사가 복잡한 소송 지원을 처리하는 것처럼 정확하고 세심함을 보여줍니다.
February 25, 2025 Health Care Law Today

GLP-1 수용체 작용제: 새로운 개척과 도전

최근 GLP-1을 기반으로 하는 새로운 종류의 약물이 당뇨병, 비만 및 비만과 관련된 기타 질환을 앓고 있는 환자의 치료와 의학에 혁명을 일으키고 있습니다.
2025년 1월 28일 이벤트

​Antibody Drug Conjugates Keep Growing: What You Need to Know

Since 2018, there has been an exponential growth of over US$60 billion of licensing deals involving Antibody Drug Conjugates (ADCs), with 2023 having at least 18 deals. ADCs worldwide are projected to reach US$20-30 billion per year in the near future.
December 17, 2024 PharmaPatents

USPTO Drops Proposed Rules on Terminal Disclaimers

Earlier in 2024, the U.S. Patent and Trademark Office proposed a sweeping set of rules imposing new requirements on terminal disclaimers filed to overcome obviousness-type double patenting rejections, and separately proposed to impose new terminal disclaimer fees that would increase exponentially over the course of examination.
장갑을 낀 손이 파란색과 보라색 박테리아 배양액이 담긴 배양 접시를 들고 있으며, 배경에는 지적 재산권으로 보호되는 혁신적인 발견처럼 흐릿한 원형 현미경 이미지가 있습니다.
December 11, 2024 Health Care Law Today

항체 약물 접합체는 계속 성장하고 있습니다: 알아야 할 사항

지난 몇 년 동안 헬스케어 및 생명과학과 혁신 기술 부문은 기업과 사모펀드 모두 투자처를 재평가하면서 거래 건수가 감소했습니다.
August 19, 2024 Deals and Wins

폴리, 선월드 인터내셔널의 바이오골드 인수에 참여하다

최근 남아프리카공화국에 본사를 둔 글로벌 과일 품종 권리 관리 업체인 바이오골드 그룹을 전략적으로 인수한 Sun World International, LLC의 주요 법률 자문사로 Foley & Lardner LLP가 선정되었습니다.